CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
Executive Summary
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
You may also be interested in...
US FDA Seeks Ability To Include More Inactive Ingredient, Excipient Info In Brand Labeling
Additions could help streamline generic development, Center for Drug Evaluation and Research Director Patrizia Cavazzoni says.
Industry Applauds US FDA Plans For Novel Excipients Review Pathway, But Urges Refinement
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
US FDA Mulls Pilot To Examine Separate Review Pathway For Novel Excipients
Proposal could yield a bounty of new options for innovative drug delivery systems.